References
- Ball, P.: Synthetic biology for nanotechnology. Nanotechnology 16:R1–R8 (2005).
- Leduc, S.: Theorie Physico-chimique de la vie et Generations Spontanees. Paris: A. Poinat, 1910. p. 202.
- Szybalski, W.: In vivo and in vitro initiation of transcription. In Control of Gene Expression. A. Kohn and A. Shatkay (Eds.). New York: Plenum Press, 1974. pp. 23–4, 404–5, 411–2, and 415–7.
- Syzbalski, W., and A. Skalka: Nobel prizes and restriction enzymes. Gene 4:181–182 (1978).
- Ad Hoc Technical Expert Group on Synthetic Biology: “Report of the Ad Hoc Technical Expert Advisory Group on Synthetic Biology. Convention on Biological Diversity.” Available at https://www.cbd.int/doc/meetings/synbio/synbioahteg-2015-01/official/synbioahteg-2015-01-03-en.pdf ( accessed May 13, 2016).
- Baker, D., G. Church, J. Collins, et al.: Engineering life: building a FAB for biology. Scientific Am. 294:44–51 (2006).
- Eisenstein, M.: Living factories of the future. Nature 531:401–403 (2016).
- Smith, H.O., C.A. Hutchison, C. Pfannkoch, and J.C. Venter: Generating a synthetic genome by whole genome assembly: фX174 bacteriophage from synthetic oligonucleotides. PNAS 100(26):15440–15445 (2003).
- Gibson, D.G., G.A. Benders, C. Andrews-Pfannkoch, et al.: Complete chemical synthesis, assembly, and cloning of a Mycoplasma genitalium genome. Science 319:1215–1219 (2008).
- Gibson, D.G., J.I. Glass, C. Lartigue, et al.: Creation of a bacterial cell controlled by a chemically synthesized genome. Science 329:52–56 (2010).
- Miller, D.M., and J.M. Gulbis: Engineering protocells: prospects for self-assembly and nanoscale production lines. Life 5:1019–1053 (2015).
- Kurihara, K., Y. Okura, M. Matsuo, T. Toyota, K. Suzuki, and T. Sugawara: A recursive vesicle-based model protocell with a primitive model cell cycle. Nature Comm. 6:1–7 (2015).
- Pinheiro, V.B., and P. Holliger: The XNA world: progress toward replication and evolution of synthetic genetic polymers. Curr. Opin. Chem. Biol. 16(3-4):245–252 (2012).
- Synthetic Biology Project: “What is Synthetic Biology?” Available at http://www.synbioproject.org/topics/synbio101/definition/ ( accessed May 15, 2016).
- Jinek, M., K. Chylinski, I. Fonfara, M. Hauer, J.A. Doudna, and E. Charpentier: A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:816–821 (2012).
- Long, C., L. Amoasii, A.A. Mireault, et al.: Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351:400–403 (2016).
- Nelson, C.E., C.H. Hakim, D.G. Ousterout, et al.: In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351(6271):403–407 (2016).
- Tabebordbar, M., K. Zhu, J.K.W. Cheng, et al.: In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351: 407–411 (2016).
- Yin, H., W. Xue, S. Chen, et al.: Genome editing with a Cas9 in adult mice corrects a disease mutation and phenotype. Nature Biotechnol. 32(6):551–553 (2014).
- Kaminski, R., Y. Chen, T. Fischer, et al.: Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing. Sci. Rep. 6:6–14 (2016).
- Naldini, L.: Gene therapy returns to centre stage. Nature 526:351–360 (2015).
- Van den Belt, H.: Playing God in Frankenstein's footsteps: Synthetic biology and the meaning of life. Nanoethics 3:257–268 (2009).
- Boldt, J.: Creating life: synthetic biology and ethics. In Synthetic Biology and Morality, G.E. Kaebnick and T.H. Murray (eds.). Cambridge, MA: The MIT Press, 2013. pp. 35–49.
- Garfinkel, M.S., D. Endy, G.L. Epstein, and R.M. Friedman: “Synthetic Biology.” Available at http://www.thehastingscenter.org/uploadedFiles/Publications/Briefing_Book/synthetic%20biology%20chapter.pdf (accessed April 26, 2016).
- Fukuyama, F.: “Transhumanism.” Available at http://foreignpolicy.com/2009/10/23/transhumanism/ ( accessed April 30, 2016).
- Tumpey, T.M., C.F. Basler, P.V. Aguilar, et al.: Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science 310:77–90 (2005).
- Sharples, F., J. Husbands, A-M. Mazza, A. Thevenon, and I. Hook-Barnard: Potential Risks and Benefits of Gain-of-function Research: Summary of a Workshop. Washington, DC: National Academies of Sciences, Engineering and Medicine, 2015.
- DIYBIO. An institution for the do-it-yourself biologist. 2016. Available at https://diybio.org/ ( accessed May 14, 2016).
- Church, G., and E. Regis: Regeneris: How Synthetic Biology will Reinvent Nature and Ourselves. New York: Basic Books, 2012.
- Pollack, A.: “Scientists Talk Privately about Creating a Synthetic Human Genome.” Available at http://www.nytimes.com/2016/05/14/science/synthetic-human-genome.html ( accessed May 14, 2016).
- Lander, E.S.: Brave new genome. New Engl. J. Med. 373(1):5–8 (2015).
- Hayden, E.C.: Tech investors bet on synthetic biology. Nature 527:19 (2015).
- Kuzma, J.: Reboot the debate on genetic engineering. Nature 531:165–167 (2016).
- Young, A., and N. Penzenstadler: “Inside America's Secretive Biolabs.” Available at http://www.usatoday.com/story/news/2015/05/28/biolabs-pathogens-location-incidents/26587505/ ( accessed April 30, 2016)
- Young, A.: “CDC Labs Repeatedly Faced Secret Sanctions for Mishandling Bioterror Germs.” Available at http://www.usatoday.com/story/news/2016/05/10/cdc-lab-secret-sanctions/84163590/ ( accessed May 12, 2016).
- Pollack, A., and D. Wilson: “Safety Rules Can't Keep Up with Biotech.” Available at http://www.nytimes.com/2010/05/28/business/28hazard.html?_r=0
- Liang, P., Y. Xu, X. Zhang, et al.: CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6(5):363–372 (2015).
- Cyranoski, D., and S. Reardon: Embryo editing sparks epic debate. Nature 620:593–594 (2015).
- Baltimore, D., P. Berg, M. Botchan, et al.: A prudent path forward for genomic engineering and germline gene modification. Science 348:36–38 (2015).
- Lanphier, E., F. Urnov, S.E. Haecker, M. Werner, and J. Smolenski: Don't edit the human germline. Nature 519:410–411 (2015).
- Pennisi, E.: “111 Organizations Call for Synthetic Biology Moratorium.” Available at http://www.sciencemag.org/news/2012/03/111-organizations-call-synthetic-biology-moratorium ( accessed May 15, 2016).
- African Biodiversity Network (Kenya), African Centre for Biosafety (South Africa), Alliance for Humane Biotechnology, et al.: “Civil Society Letter to President's Commission on Synthetic Biology.” Available at http://www.geneticsand-society.org/article.php?id=5517 ( accessed May 11, 2016).
- U.S. Department of Health and Human Services: “Screening Framework Guidance for Providers of Synthetic Double-stranded DNA.” Available at http://www.phe.gov/Preparedness/legal/guidance/syndna/Documents/syndna-guidance.pdf ( accessed April 30, 2016).
- U.S. Department of Health and Human Services: “Dual Use Research of Concern.” Available at http://www.phe.gov/s3/dualuse/Pages/default.aspx ( accessed June 30, 2016).
- Tucker, J.B.: Could terrorists exploit synthetic biology? The New Atlantis, Spring 2011.
- Tucker, J.B., and R.A. Zilinskas: The promise and perils of synthetic biology. The New Atlantis, Spring, 2006.
- International Risk Governance Council: Guidelines for the Appropriate Risk Governance of Synthetic Biology. Available at http://www.irgc.org/IMG/pdf/irgc_SB_final_07jan_web.pdf ( accessed April 22, 2016).
- Office of Science Technology and Policy (OSTP): Coordinated Framework for Regulation of Biotechnology. Available at http://www.aphis.usda.gov/brs/fedregister/coordinated_framework.pdf ( accessed April 28, 2016).
- Code of Federal Regulations: “Bloodborne Pathogens.” Available at https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&p_id=10051 ( accessed May 14, 2016).
- Code of Federal Regulations: “Toxic and Hazardous Substances.” Available at https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_id=9991&p_table=STANDARDS ( accessed May 14, 2016).
- Code of Federal Regulaions: “Access to Employee Exposure and Medical Records.” Available at https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&p_id=10027 ( accessed May 14, 2016).
- Code of Federal Regulaions: “Hazard Communication.” Available at https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=standards&p_id=10099 ( accessed May 14, 2016).
- Code of Federal Regulaions: “Occupational Exposure to Hazardous Chemicals in Laboratories.” Available at https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&p_id=10106 ( accessed May 14, 2016).
- Code of Federal Regulaions: “Respiratory Protection.” Available at https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&p_id=12716 ( accessed May 14, 2016).
- “Exercise of Federal Oversight within Scope of Statutory Authority: Planned Introductions of Biotechnology Products into the Environment,” Federal Register 57:39 ( February 27, 1992). pp. 6753–6762.
- Holdren, J., H. Shlanski, D. Vetter, and C. Goldfuss: “Modernizing the regulatory system for biotechnology products.” Available at https://www.whitehouse.gov/sites/default/files/microsites/ostp/modernizing_the_reg_system_for_biotech_products_memo_final.pdf ( accessed May 14, 2016).
- Barbero, R., and J. Kim: “Clarifying Current Roles and Responsibilities for Biotechnology Products.” Available at https://www.whitehouse.gov/blog/2016/03/07/clarifying-current-roles-and-responsibilities-biotechnology-products ( accessed April 30, 2016).
- Ledford, H.: Gene editing surges as U.S. rethinks regulations. Nature 532:158–159 (2016).
- Occupational Safety and Health Administration (OSHA): “Infectious Disease Rulemaking.” Available at https://www.osha.gov/dsg/id/ ( accessed May 14, 2016).
- Bergeson, L.L., L.M. Campbell, S.L. Dolan, et al.: “The DNA of the U.S. Regulatory System: Are We Getting it Right for Synthetic Biology?” Available at http://www.synbioproject.org/publications/dna-of-the-u.s-regulatory-system/ ( accessed on May 10, 2016).
- Carter, S.R., M. Rodemeyer, M.S. Garfinkel, and R. Friedman: “Synthetic Biology and the U.S. Biotechnology Regulatory System: Challenges and Options.” Available at http://www.jcvi.org/cms/research/projects/synthetic-biology-and-the-us-biotechnology-regulatory-system/overview/ ( accessed May 9, 2016).
- J. Craig Venter Institute: Synthetic Biology and the U.S. Biotechnology Regulatory System: Challenges and Options. La Jolla, CA: J. Craig Venter Institute, 2014.
- Lowrie, H., and J. Tait: “Policy Brief: Guidelines for the Appropriate Risk Governance of Synthetic Biology.” Available at http://www.irgc.org/IMG/pdf/irgc_SB_final_07jan_web.pdf( accessed May 10, 2016).
- Friends of the Earth U.S., International Center for Technology Assessment, and ETC Group: “The Principles for the Oversight of Synthetic Biology, 2010.” Available at http://www.synbioproject.org/process/assets/files/6620/_draft/principles_for_the_oversight_of_synthetic_biology.pdf ( accessed May 10, 2016).
- Garfinkel, M.S., D. Endy, G.L. Epstein, and R.M. Friedman: “Synthetic Genomics: Options for Governance.” Available at http://www.synbiosafe.eu/uploads/pdf/Synthetic%20Genomics%20Options%20for%20Governance.pdf ( accessed May 14, 2016).
- World Health Organization (WHO): “Laboratory Biosafety Manual. 3rd ed.” Available at http://www.who.int/csr/resources/publications/biosafety/Biosafety7.pdf?ua=1 (accessed May 14, 2016).
- U.S. Department of Health and Human Services: “Biosafety in Microbiological and Biomedical Laboratories, 5th ed.” Available at http://www.cdc.gov/biosafety/publications/bmbl5/index.htm ( accessed December 23, 2015).
- National Science Advisory Board for Biosecurity (NSABB): “Addressing Biosecurity Concerns related to Synthetic Biology.” Available at http://osp.od.nih.gov/sites/default/files/resources/NSABB%20SynBio%20DRAFT%20Report-FINAL%20%282%29_6-7-10.pdf ( accessed on May 14, 2016)
- National Institutes of Health (NIH): “NIH Guidelines for Research involving Recombinant or Synthetic Nucleic Acid Molecules.” Available at http://osp.od.nih.gov/office-biotechnology-activities/biosafety/nih-guidelines ( accessed May 14, 2016).
- U.S. Department of Health and Human Services: “United States Government Policy for Institutional Oversight of Life Science Dual Use Research of Concern.” Available at http://www.phe.gov/s3/dualuse/documents/durc-policy.pdf ( accessed June 30, 2016).
- Bailey, C., H. Metcalf, and B. Crook: “Synthetic Biology: A Review of the Technology, and Current and Future Needs from the Regulatory Framework in Great Britain.” Available at http://www.hse.gov.uk/research/rrpdf/rr944.pdf ( accessed May 22, 2016).
- Pauwels, K, N. Willemarck, D. Breyer, and P. Herman: “Synthetic Biology: Latest Developments, Biosafety Considerations and Regulatory Challenges.” Available at http://www.biosafety.be/PDF/120911_Doc_Synbio_SBB_FINAL.pdf ( accessed May 22, 2016).
- Netherlands Commission on Genetic Modification: “Biological Machines? Anticipating Developments in Synthetic Biology.” Available at: http://www.cogem.net/index.cfm/en/publications/publication/biological-machines-anticipating-developments-in-synthetic-biology (accessed November 15, 2016).
- European Commission (EC): “Opinion on Synthetic Biology II: Risk Assessment Methodologies and Safety Aspects. European Union.” Available at http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_048.pdf ( accessed May 12, 2016).
- Breitling, R., E. Takano, and T.S. Gardner: Judging synthetic biology risks. Science 347;107 (2015).
- Bar-Yam, S., J. Byers-Corbin, R. Casagrande, et al.: “The Regulation of Synthetic Biology: A Guide to United States and European Union Regulations, Rules And Guidelines.” Available at https://www.synberc.org/sites/default/files/Concise%20Guide%20to%20Synbio%20Regulation%20OYE%20Jan%202012_0.pdf ( accessed May 14, 2016).
- Tucker, J.B.: Introduction. In Innovation, Dual-Use and Security: Managing the Risks of Emerging Biological and Chemical Technologies, J.B. Tucker (ed.) Cambridge, MA: MIT Press, 2012. pp. 4–6.
- Cong, L., F.A. Ran, S. Cox, et al.: Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823 (2013).
- McNutt, M.: Breakthrough to genome editing. Science 350:1445 (2015).
- Ledford, H.: CRISPR, the disruptor. Nature 522:20–24 (2015).
- Travis, J.: Making the Cut: CRISPR genome-editing technology shows its power. Science 350:1456–1457 (2015).
- Cookson, C.: UK Scientists given green light to ‘edit’ genes in human embryos. Financial Times, February 1, 2016.
- Blaese, R.M., K.W. Culver, A.D. Miller, et al.: T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 270: 475–480 (1995).
- Cross, D., and J.K. Burmester: Gene therapy for cancer treatment: Past, present and future. Clin. Med. Res., 4(3):218–227 (2006).
- Merten, O-W, and M. Al-Rubeai: Viral Vectors for Gene Therapy. New York: Human Press, 2011.
- Robbins, P.D., and S.C. Ghivizzani: Viral vectors for gene therapy. Pharmacol. Ther. 80(1): 35–47 (1998).
- Levine, B.L., L.M. Humeau, J. Boyer, et al.: Gene transfer in humans using a conditionally replicating lentiviral vector. PNAS 103(46):17372–17377 (2006).
- Maetzig, T., M. Galla, C. Baum, and A. Schambach: Gammaretroviral vectors: Biology, technology and application. Viruses 3:677–713 (2011).
- Tomas, H.A., A.F. Rodriquez, P.M. Alves, and A.S. Corodinha: “Lentiviral Gene Therapy Vectors: Challenges and Future Directions.” Available at http://www.intechopen.com/books/gene-therapy-tools-and-potential-applications/lentiviral-gene-therapy-vectors-challenges-and-future-directions ( accessed May 13, 2016).
- Howard J.: HIV infection in the workplace. The Occupational and Environmental Medicine Report 4(8):60–64 (1990).
- Beckwith, C.G., E.J. Wing, B. Rodriguez, and M.M. Lederman: Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome. In Cecil Essentials of Medicine, T.E. Andreoli, I. Benjamin, R.C. Griggs, and E.J. Wing (eds.). Philadelphia, PA: Saunders, 2010. pp. 1008–1027.
- Sakuma, T, M.A. Barry, and Y. Ikeda: Lentiviral vectors: basic to translational. Biochem. J. 443:603–618 (2012).
- Journal of Gene Medicine: “Gene Therapy Clinical Trials Worldwide.” Available at http://www.wiley.com/legacy/wileychi/genmed/clinical/ ( accessed May 13, 2016).
- Pauwels, K., R. Gijsbers, J. Toelen, et al.: State-of-the-art lentiviral vectors for research use: risk assessment and biosafety recommendations. Curr. Gene Ther. 9:459–474 (2009).
- Cronin, J., X-Y Zhang, and J. Reiser: Altering the tropism of lentiviral vectors through pseudotyping. Curr. Gene Ther. 5(4):387–398 (2005).
- Schambach, A., D. Zychlinski, B. Erhnstroem, and C. Baum: Biosafety features of lentiviral vectors. Hum. Gene Ther. 24:132–142 (2013).
- Mosier, D.E.: Introduction for ‘Safety considerations for retroviral vectors: a short review’. Appl. Biosaf. 9(2):68–75 (2004).
- Wright, O., G-B. Stan and T. Ellis: Building-in biosafety for synthetic biology. Microbiology 159:1221–1235 (2013).
- Alteri, C., A. Soria, A. Bertoli, et al.: “HIV-1 Laboratory Contagion during Recombination Procedures with Defective Constructs.” Available at http://www.croi-conference.org/sessions/hiv-1-laboratory-contagion-during-recombination-procedures-defective-constructs ( accessed April 25, 2016).
- Hacen-Bey-Abina, S., C. Von Kalle, M. Schmidt, et al.: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302:415–419 (2003).
- Hacen-Bey-Abina, S., A. Garrigue, and G.P. Wang: Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118(9):3132–3142 (2008).
- Howe, S.J., M.R. Mansour, and K. Schwarzwaelder: Insertional mutagenesis combined with somatic mutations causes leukemogensis following gene therapy of SCID-X1 patients. J Clin. Invest. 118(9):3143–3250 (2008).
- Persons, D.A.: Lentiviral vector gene therapy: effective and safe? Molec. Ther. 18(5): 861–862 (2010).
- Berg, P., D. Baltimore, S. Brenner, R.O. Roblin III, and M.F. Singer: Summary statement of the Asilomar Conference on Recombinant DNA Molecules. PNAS 72(6):1981–1984 (1975).
- LaVan, D.A., and L.M. Marmon: Safe and effective synthetic biology. Nat. Biotech. 28(10):1010–1012 (2010).
- Carlson, R.: Estimating the biotech sector's contribution to the US economy. Nat. Biotech. 34(3):247–255 (2016).
- White House: “National Bioeconomy Blueprint.” Available at https://www.whitehouse.gov/sites/default/files/microsites/ostp/national_bioeconomy_blueprint_april_2012.pdf ( accessed May 10, 2016).
- U.S. Department of Defense (DOD): “Technical Assessment: Synthetic Biology.” Available at http://defenseinnovationmarketplace.mil/resources/OTI-SyntheticBiologyTechnicalAssessment.pdf ( accessed May 22, 2016)
- Synthetic Biology Leadership Council: “Biodesign for the Bioeconomy: UK Synthetic Biology Strategic Plan 2016.” Available at http://www.synbio.cam.ac.uk/news/synbio-strategic-plan-2016 ( accessed July 2, 2016).
- “Biotechnology,” Federal Register 50:12 ( 12 April 1985). pp. 14468–14470.
- Schulte, P., D.J. Mundt, M. Nasterlack, K.B. Mulloy, and K.A. Mundt: Exposure registries: overview and utility for nanomaterial workers. J Occup Environ Med 53(6 Suppl.):S42–47 (2011).
- Murashov, V., and J. Howard: Essential features of proactive risk management. Nat. Nanotechnol. 4: 467–470 (2009).
- Weick, K.E., Sutcliffe, K.M.: Managing the Unexpected: Sustained Performance in a Complex World. Hoboken, NJ: Wiley and Sons, 2015.
- Trevan, T.: Biological research: rethink biosafety. Nature 527:155–158 (2015).
- Schulte, P., R. Rinehart, A. Okun, G.L. Geraci, and D.S. Heidel: National prevention through design (PtD) initiative. J Safety Res 39(2):115–121 (2008).
- Erickson, R., H.R. Sing, and P. Winters: Synthetic biology: regulating industry uses of new biotechnologies. Science 333:1254–1256 (2011).
- Schmidt, M.: Introduction. In Synthetic Biology: Industrial and Environmental Applications, M. Schmidt (ed.). Weinheim, Germany: Wiley-Blackwell, 2012. pp. 1–6.
- Rohn, J.: Synthetic biology goes industrial. Nat. Biotechnol. 31:773 (2013).
- National Institute for Occupational Safety and Health (NIOSH): “The State of the National Initiative on Prevention through Design. Centers For Disease Control And Prevention.” Available at http://www.cdc.gov/niosh/docs/2014-123/pdfs/2014-123.pdf ( accessed May 14, 2016)
- Cai, Y., N. Agmon, W.J. Choi, et al.: Intrinsic biocontainment: multiplex genome safeguards combine transcriptional and recombinational control of essential yeast genes. PNAS 112(6): 1803–1808 (2015).
- Schmidt, M., and V. de Lorenzo: Synthetic constructs in/for the environment: managing the interplay between natural and engineered biology. FEBS Letters 586:2199–2206 (2012).
- Steidler, L., S. Neirynck, N. Huyghebaert, et al.: Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol. 21:785–789 (2003).
- Cockrell, A.S., H. Ma, K. Fu, T.J. McCown, and T. Kafri: A trans-lentiviral packaging cell line for high-titer conditional self-replicating HIV-1 vectors. Molec. Ther. 14(1):276–284 (2006).
- Zufferey, R., T. Dull, R.J. Mandel, et al.: Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72(12):9873–9880 (1998).
- Gallagher, R.R., J.R. Patel, A.L. Interiano, A.J. Rovner, and F.J. Isaacs: Multilayered genetic safeguards limit growth of microorganisms to defend environments. Nucl. Acids Res. 43(3):1945–1954 (2015).
- Chan, C.T.Y., J.W. Lee, E. Cameron, C.J. Bashor, and J.J. Collins: ‘Deadman’ and ‘passcode’ microbial kill switches for bacterial containment. Nat. Chem. Biol. 12:82–86 (2016).
- Bej, A.K., M.H. Perlin, and R.M. Atlas: Model suicide vector for containment of genetic engineered microorganisms. Appl. Environ. Microbiol. 54(10):2472–2477 (1988).
- Bokhoven, M., S.L. Stephen, S. Knight, et al.: Insertional gene activation by lentiviral and gammaretroviral vectors. J. Virol. 83(1):283–294 (2009).
- Schmidt, M.: Xenobiology: A new form of life as the ultimate biosafety tool. BioEssays 32(4):322–331 (2010).
- Garfinkel, M.: “Biological Containment of Synthetic Microorganisms: Science and Policy.” Available at http://www.embo.org/documents/science_policy/biocontainment_ESF_EMBO_2012_workshop_report.pdf ( accessed April 30, 2016).
- “Working With Viral Vectors.” Available at https://web.stanford.edu/dept/EHS/prod/researchlab/bio/docs/Working_with_Viral_Vectors.pdf ( accessed May 11, 2016).
- Biosafety Office: “Lentiviral Vectors.” Available at http://research-compliance.uc.edu/training/lentiviral-vectors/story_content/external_files/LV%20online%20%28March%202014b%29.pdf ( accessed May 15, 2016).
- Gray, J.T.: Laboratory safety for oncogene-containing retroviral vectors. Appl. Biosaf. 16(4):218–222 (2011).
- Byers, K.B.: Biosafety tips. Appl. Biosaf. 20:250–252 (2015).
- American Biological Safety Association (ABSA): “Lentivirus Vector Fact Sheet.” Available at https://www.absa.org/pdf/LentivirusVectorFactSheet.pdf ( accessed April 21, 2016).
- National Institutes of Health (NIH): “Biosafety Considerations for Research With Lentiviral Vectors.” Available at http://osp.od.nih.gov/sites/default/files/resources/Lenti_Containment_Guidance_0_0.pdf ( accessed on May 12, 2016).
- National Institute for Occupational Safety and Health (NIOSH): “Approaches to Safe Nanotechnology: Managing the Health and Safety Concerns Associated With Engineered Nanomaterials.” Available at http://www.cdc.gov/niosh/docs/2009-125/pdfs/2009-125.pdf ( accessed May 12, 2016).
- Murashov V., and J. Howard: The U.S. must help set international standards for nanotechnology. Nat. Nanotechnol. 3:635–636 (2008).
- Murashov, V., P. Schulte, C. Geraci, and J. Howard: Regulatory approaches to worker protection in nanotechnology industry in the USA and European Union. Industr. Health 49:280–296 (2011).
- Murashov, V., and J. Howard: Risks to health care workers from nano-enabled medical products. J. Occ. Env. Hyg. 12(6):D75–D85 (2015).
- Baggaley, R., M. Doherty, A. Ball, N. Ford, and G. Hirnschall: The strategic use of antiretrovirals to prevent HIV infection: A converging agenda. Clin. Infect. Dis. 60(Supp 3):S159–S160 (2015).
- Centers for Disease Control and Prevention (CDC): “Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016.” Available at http://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf ( accessed May 12, 2016).
- Kuhar, J.T., D.K. Hendersen, K.A. Struble, et al.: “Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis” Available at https://stacks.cdc.gov/view/cdc/20711 ( accessed May 14, 2016).
- Warnock, J.N., C. Daigre, and M. Al-Rubeai: Introduction to viral vector. In Viral Vectors, O-W. Merten and M. Al-Rubeai (Eds.), New York: Humana Press. p. 1.
- Presidential Commission for the Study of Biomedical Issues: “New Directions: The Ethics of Synthetic Biology and Emerging Technologies.” Available at http://bioethics.gov/synthetic-biology-report ( accessed May 21, 2016).
- Moe-Behrens, G.H.G, R. Davis, and K.A. Haynes: Preparing synthetic biology for the world. Front. Microbiol. 4(5):1–10 (2013).